Skip to main content
. Author manuscript; available in PMC: 2021 Aug 9.
Published in final edited form as: J Immunol. 2010 Dec 6;186(1):214–221. doi: 10.4049/jimmunol.1001172

Figure 3.

Figure 3.

Allospecific TCR75 CD4+ T cells proliferate in the presence of anti-Kd mAbs. CFSE-labeled TCR75 TCR-Tg T cells (0.25 x 106) were injected i.v. at the time of skin transplantation. TCR75 T cells were harvested from the draining lymph nodes five days later and proliferation was measured by flow cytometry. Representative histogram of TCR75 T cell proliferation from untransplanted B6 recipients (naïve B6) ( 1st Panel), B6 recipients of BALB/c grafts without treatment (No Rx) (2nd Panel), treated with anti-CD154/DST (αCD154/DST ) (3rd Panel), or with anti-CD154/DST and anti-Kd mAbs (αCD154/DST + αKd) (4th Panel). The percentage of dividing TCR75Tg T cells from individual mice in each group are summarized (N = 3/ group). Significantly higher percentages of proliferating TCR75 Tg T cells were observed in B6 recipients treated with anti-Kd mAbs and anti-CD154/DST compared to recipients treated with anti-CD154/DST (p = 0.0067).